pharmaceuticals

pharmaceuticals Articles

It is no secret that pharma and biotech shares have had to deal with at least some headwinds over the past year. It turns out that drug pricing concerns and political oversight can still be...
Sangamo Therapeutics saw its shares skyrocket early on Thursday after a critical business update.
The April 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly downward.
The analysts at Stifel have focused on biotech and specialty pharma companies that not only have data that could prove to be huge, but they are offering aggressive accounts the best entry points in...
With earnings this positive and shares responding as a result, investors have to wonder if Valeant Pharmaceuticals is for real this time, or is this just a head fake.
Horizon Pharma PLC (NASDAQ: HZNP) saw its shares hit a 52-week low on Monday after the company released its first-quarter financial results. The company said that it had $0.21 in EPS and $220.9...
JPMorgan has made the case that the best place for investors to look when considering large cap drug stocks is companies that have strong new product cycles already in motion.
Shares of Pieris Pharmaceuticals saw perhaps one of the biggest gains on Wednesday after the company announced a critical collaboration with AstraZeneca.
Pfizer reported mixed first-quarter financial results before the markets opened on Tuesday.
Following the closing of the sale of three skincare brands to L'Oréal and after the closing of the divestiture of a manufacturing facility in Brazil, Valeant said that it now has further reduced its...
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Shares of Immune Pharmaceuticals saw an incredible gain in Thursday’s session following the announcement of an exclusive license agreement.
Over the past five, 10 and 20 years, the life science and bioproduction segments have tended to outperform the S&P 500 more often than not.
Arena Pharmaceuticals saw its shares drop sharply on Tuesday after the company announced a secondary offering of 60 million shares of its common stock.
When drugs are expected to get FDA approval and show positive data but don't, the underlying stocks of drug and biotech companies can see harsh punishment.